Persistent organic pollutants (POPs) are organic chemical compounds that are highly toxic, persist in the environment, bioaccumulate in fatty tissues of living organisms, travel long distances, and naturally flow toward colder climates ([@b1-ehp0115-000883]). Humans are generally exposed to POPs through their food supply ([@b1-ehp0115-000883]).

Whether the exposure to endocrine disruptors such as POPs at current background environmental levels is harmful to human health has become a matter of intense debate, politically and scientifically ([@b16-ehp0115-000883]). However, we recently reported striking associations of serum concentrations of several POPs with diabetes in a random sample of the general population with background exposure to POPs ([@b21-ehp0115-000883]). In a recent editorial ([@b20-ehp0115-000883]), we discussed that selection of a reference group with a known very low exposure is critical in the estimation of POPs-associated risks. This is because risks of several POPs-associated conditions appear to increase substantially even within a narrow range of low POPs concentrations, not detectable without substantial blood volume. Thus, epidemiologic studies on POPs in the general population could identify strong associations that might have been missed in previous epidemiologic studies in people exposed to high concentrations of selected POPs that used the general population as the reference group, as if its substantial range of exposure had uniform risk.

In the present study we hypothesized that background environmental exposure to POPs is also involved in pathogenesis of arthritis. Among the various subtypes of arthritis, rheumatoid arthritis (RA) and osteoarthritis (OA) are the two most common in the general population ([@b2-ehp0115-000883]). RA is an autoimmune disease in which an as yet unknown trigger results in a chronic inflammatory process affecting the synovial membrane of the joints ([@b14-ehp0115-000883]), while OA is often thought to result from natural aging processes on the joint surfaces ([@b34-ehp0115-000883]). Although much is known about the pathophysiology of these conditions at a cellular level, there is considerably less information about the etiology of RA and OA in general population studies.

Endocrine disruptors such as POPs markedly influence the immune system ([@b3-ehp0115-000883]), which could increase the risk of autoimmune diseases such as RA. In addition, beyond the negative effects of increased weight bearing caused by obesity, metabolic change due to adipose tissue has recently been proposed as one underlying mechanism of osteoarthritis ([@b12-ehp0115-000883]). Because POPs stored in adipose tissue can be related to differentiation, metabolism, and function in adipose tissue ([@b24-ehp0115-000883]), POPs could be involved in the relation between obesity and OA. Furthermore, the relations of POPs with arthritis may be different depending on sex because endocrine disruptors such as POPs may exert their effects through sex hormone-related receptors ([@b6-ehp0115-000883]).

The population-based National Health and Nutrition Examination Survey (NHANES) 1999--2002 measured background concentrations of a variety of POPs. This survey also obtained self-report of clinical diagnosis of history of arthritis and subtypes of arthritis. Although the validity of report of all types of arthritis combined is high, validity of the subtype of arthritis based on questionnaire has been reported to be low ([@b35-ehp0115-000883]). Given this fact, the predominance of RA and OA among all arthritis types, and our hypothesis that jointly involved RA and OA, we primarily focused our investigation on the association between serum concentrations of POPs and prevalence of all arthritis and further analyzed by the subtype of arthritis.

Materials and Methods
=====================

The 1999--2002 NHANES conducted by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) was designed to be nationally representative of the noninstitutionalized U.S. civilian population on the basis of a complex, multistage probability sample. Details of the NHANES protocol and all testing procedures are available elsewhere ([@b27-ehp0115-000883], [@b28-ehp0115-000883]). Serum concentrations of biologically important POPs or their metabolites were measured in subsamples of the NHANES 1999--2002 ([@b26-ehp0115-000883]). The study protocol was reviewed and approved by the CDC institutional review board; additionally, informed written consent was obtained from all subjects before they took part in the study.

The NHANES standardized home interview was followed by a detailed physical examination in a mobile evaluation clinic or the participant's home ([@b27-ehp0115-000883], [@b28-ehp0115-000883]). Information about existing medical conditions was collected using questionnaires. Venous blood samples were collected and shipped weekly at --20°C. POPs were measured by high-resolution gas chromatography/high-resolution mass spectrometry using isotope dilution for quantification. All of these analytes were measured in approximately 5 mL serum using a modification of the method of [@b39-ehp0115-000883]. Ability to detect low POPs concentrations was greater in those participants who provided a larger aliquot. The POPs were reported on a lipid-adjusted basis using concentrations of serum total cholesterol and triglycerides.

Although 49 POPs were measured in both NHANES 1999--2000 and 2001--2002, to avoid bias in estimation among those below the limit of detection (LOD) we selected the 19 POPs for which at least 60% of study subjects had concentrations \> LOD; 3 polychlorinated dibenzo-*p*-dioxins (PCDDs), 3 polychlorinated dibenzofurans (PCDFs), 4 dioxin-like polychlorinated biphenyls (PCBs), 5 nondioxin-like PCBs, and 4 organochlorine (OC) pesticides. A total of 1,721 study participants were ≥ 20 years of age with information available on serum concentrations of the 19 selected POPs.

For each POP, subjects with serum concentrations \< LOD were regarded as the reference group, and subjects with detectable values were categorized into quartiles by cutoff points of 25th, 50th, and 75th values. To yield a cumulative measure (which would provide a cumulation of risk across POPs with similar chemical and physical properties) of 3 PCDDs, we summed the rank of 3 POPs that belong to the PCDDs. The summary values were categorized into quartiles by cutoff points of 25th, 50th, and 75th values. We categorized and cumulated POP subclasses similarly for the 3 PCDFs, the 4 dioxin-like PCBs, the 5 non-dioxin-like PCBs, and the 4 OC pesticides. For example, a subject had rank 0 for all POPs with serum concentrations \< LOD. For other POPs with a detectable level, the participant was ranked accordingly. Thus, depending on the sum of ranks of the several POPs belonging to the specific POP subclass under consideration, the subject could be in the lowest quartile or in a higher quartile; however, if all POPs in the subclass were nondetectable, the subject would be placed in the lowest quartile. We chose the current approach because there is no scientific rationale for summing within the POP subclasses to create broader exposure categories.

Participants were considered to have prevalent arthritis if they answered "yes" to the following question: "Has a doctor or other health professional ever told you that you had arthritis?" They were further asked about the type of arthritis. We used logistic regression models to calculate multivariate-adjusted odd ratios (ORs) and 95% confidence intervals (CIs). All analyses were performed separately in men and women. Adjusting variables were age (years), race/ethnicity, poverty income ratio (continuous), body mass index (BMI; continuous), and cigarette smoking (never, former, or current). We substituted median values of noncases for missing BMI or poverty income ratio in 83 subjects; exclusion of these individuals did not change any conclusions.

We performed all statistical analyses with SAS 9.1 (SAS Institute Inc., Cary, NC, USA) and SUDAAN 9.0 (Research Triangle Institute, Research Triangle Park, NC, USA). Estimates of main results were calculated accounting for stratification and clustering ([@b18-ehp0115-000883]), adjusting for age, race and ethnicity, and poverty income ratio instead of using sample weights; this adjustment is a good compromise between efficiency and bias ([@b15-ehp0115-000883]; [@b18-ehp0115-000883]). Because results were very similar with SAS 9.1 and SUDAAN 9.0, we present the results based on SAS 9.1.

Results
=======

The sample of 1,721 participants was 44.7% male, 47.7% white, and 16.9% current smokers. Mean ± SD for age was 49.2 ± 19.0 years (range 20--85 years). [Table 1](#t1-ehp0115-000883){ref-type="table"} shows the associations of five subclasses of POPs with demographic or health behavior factors. Age was the strongest and most important correlate of serum concentrations of all five subclasses of POPs in both sexes, with correlation coefficients ranging from 0.35 to 0.72. White subjects had lower concentrations of OC pesticides in both sexes and lower PCDDs in females, but higher concentrations of PCDFs and PCBs. Those with higher income had lower concentrations of OC pesticides but higher PCBs. Males with higher BMI tended to have higher concentrations of most POPs; however BMI was not associated with POPs among females, except in the inverse association with nondioxin-like PCBs. Current smokers tended to have lower concentrations of most POPs. After adjusting for age, we found positive pairwise correlations among serum concentrations of the five subclasses of POPs with correlation coefficients from 0.24 to 0.73 in men and 0.19 to 0.77 in women. Women had higher serum concentrations of all five subclasses of POPs with age-adjusted correlation coefficients with sex of 0.22--0.34.

There were 414 prevalent self-reported arthritis cases (164 men and 250 women): 93 RA, 116 OA, 37 other types of arthritis, and 168 unspecified arthritis cases. Neither PCDDs nor PCDFs were associated with arthritis in either sex. However, women who had higher concentrations of dioxin-like PCBs or nondioxin-like PCBs showed a higher risk of prevalence of arthritis ([Table 2](#t2-ehp0115-000883){ref-type="table"}). After adjusting for age, race/ethnicity, poverty income ratio, BMI, and smoking, ORs were 1.0, 2.1, 3.5, and 2.9 across quartiles of dioxin-like PCBs (*p* for trend = 0.02). Corresponding figures for nondioxin-like PCBs were 1.0, 1.6, 2.6, and 2.5 (*p* for trend = 0.02). OC pesticides were weakly associated with the prevalence of arthritis among women; adjusted ORs were 1.0, 1.2, 1.3, and 1.8 (*p* for trend = 0.09) ([Table 2](#t2-ehp0115-000883){ref-type="table"}). We also performed analyses adjusting for sex (males and females in one model); adjusted ORs for dioxin-like PCBs were 1.0, 1.6, 2.1, and 2.0 (*p* for trend = 0.02) and those for nondioxin-like PCBs were 1.0, 1.4, 3.0, and 2.1 (*p* for trend \< 0.01). However, we found little association among males ([Table 2](#t2-ehp0115-000883){ref-type="table"}), and we observed significant *p*-values for sex interaction: 0.03 for dioxin-like PCBs and 0.04 for nondioxin-like PCBs. When the study subjects were stratified by age (\< 50 and ≥ 50 years) or obesity (BMI \< 30 and ≥ 30), the associations were similar to those in [Table 2](#t2-ehp0115-000883){ref-type="table"}. Most specific POPs belonging to the subclasses of dioxin-like and nondioxin-like PCBs and OC pesticides were positively associated with arthritis among women ([Table 3](#t3-ehp0115-000883){ref-type="table"}).

For subtypes of arthritis among women, RA (*n* = 93) was more strongly associated with dioxin-like PCBs, nondioxin-like PCBs, or OC pesticides than was OA (*n* = 116) ([Table 4](#t4-ehp0115-000883){ref-type="table"}). The adjusted ORs (by quartile) for RA were 1.0, 7.6, 6.1, and 8.5 for dioxin-like PCBs (*p* for trend = 0.05), 1.0, 2.2, 4.4, and 5.4 for nondioxin-like PCBs (*p* for trend \< 0.01), and 1.0, 2.8, 2.7, and 3.5 for OC pesticides (*p* for trend = 0.15). Adjusted ORs for unspecified arthritis subtype (*n* = 168) were weaker than those of RA but stronger than those of OA ([Table 4](#t4-ehp0115-000883){ref-type="table"}), as we expected because these cases were likely a mixture of mostly RA and OA.

In all analyses, we also considered possible confounding by self-reported weight loss in the 1 year or in the 10 years before examination, because weight loss has been reported to increase serum concentrations of POPs ([@b5-ehp0115-000883]). However, the adjustment for weight loss did not materially change the results (data not shown). Additionally, we investigated the associations after excluding subjects with diabetes or cardiovascular diseases, but the results were not different (data not shown).

Discussion
==========

In the present study, background exposure to some kinds of POPs was positively associated with arthritis among women. Especially, among the two most common subtypes of arthritis, RA showed much stronger associations with POPs than did OA, and those associations were of intermediate strength in those with unspecified arthritis type. The validity of self-reported RA is low ([@b35-ehp0115-000883]). However, because subjects did not know their serum levels of POPs and because their exposure to POPs was mainly due to background exposure, nondifferential misclassification is the most likely consequence of reduced reliability, leading to attenuated strength of association. In this case, null associations could be falsely negative; however, the clear positive associations among women would not be explained by the low validity of RA. In spite of the cross-sectional design, our findings are biologically plausible; this is the first study in the general population with background exposure to POPs. Whether low-dose environmental exposure to POPs in humans could be harmful is one of the most controversial issues in the field of toxicology ([@b16-ehp0115-000883]; [@b32-ehp0115-000883]; [@b43-ehp0115-000883]). However, few epidemiologic studies have been carried out for POPs in the general population, even in a cross-sectional design. The absence of epidemiologic studies in the general population is understandable given the cost of measuring of a variety of POPs and the substantial amount of serum required for their measurement.

Endocrine disruptors such as POPs markedly influence the immune system ([@b3-ehp0115-000883]), but the possibility that the human immune system may respond to a low concentration of POPs has not been studied specifically. However, one might infer such an immune response even to the exposure to the background exposure to POPs on the basis of associations of POPs with diabetes in the general population, which we have reported in this same data set ([@b21-ehp0115-000883]). Among the POPs examined in the present study, PCBs were most strongly associated with RA, and the associations did not differ depending on chemical and physical properties of specific PCBs (dioxin-like or nondioxin-like). Interestingly, the known decreasing concentrations of PCBs appear to be consistent with decreasing secular trends of RA over several recent decades in the United States ([@b4-ehp0115-000883]; [@b11-ehp0115-000883]).

The different associations between PCBs and RA by sex we report here may be biologically plausible because sex hormones appear to play an important role as modulators of autoimmune disease onset and perpetuation, as in the case of RA ([@b7-ehp0115-000883]). Generally, steroid hormones are implicated in the immune response, with estrogens as enhancers at least of the humoral immunity and androgens, progesterone, and glucocorticoids as natural immunosuppressors ([@b7-ehp0115-000883]). Thus, different effects of PCBs by sex may be also possible because endocrine disruptors such as POPs may exert some of their toxicologic effects through sex hormone--related receptors ([@b6-ehp0115-000883]; [@b40-ehp0115-000883]).

Until now, reports of the effects of PCBs on immune function have focused primarily on immunosuppression, with changes in both humoral and cellular immunity ([@b13-ehp0115-000883]; [@b17-ehp0115-000883]; [@b22-ehp0115-000883]; [@b25-ehp0115-000883]; [@b36-ehp0115-000883]; [@b41-ehp0115-000883]; [@b42-ehp0115-000883]). Studies on specific clinical correlates have suggested increased prevalence of middle ear ([@b10-ehp0115-000883]; [@b42-ehp0115-000883]) and other bacterial infections ([@b37-ehp0115-000883]). Limited information exists on the potential effects of PCBs on autoimmunity. Most epidemiologic studies on autoimmunity have measured cellular or humoral immunologic function, such as numbers in lymphocyte subpopulations, *in vitro* lymphocyte response, plasma cytokine levels, or autoantibodies. However, the results have not been consistent. Although some studies have reported positive associations ([@b8-ehp0115-000883]; [@b19-ehp0115-000883]), other studies failed to do so ([@b33-ehp0115-000883]; [@b37-ehp0115-000883]; [@b38-ehp0115-000883]; [@b44-ehp0115-000883]).

In addition to PCBs in the present study, we found that some pesticides were positively associated with RA among women. Previous studies on the association between pesticides and RA have been inconsistent. Several epidemiologic studies have reported increased RA or increased prevalence of antinuclear antibody among farmers ([@b23-ehp0115-000883]; [@b29-ehp0115-000883]; [@b31-ehp0115-000883]), but others did not ([@b9-ehp0115-000883]). Interpretation of previous studies may be limited because the exposure assessment was based on questionnaires about exposure to pesticides rather than on direct measurement of pesticide concentrations in blood.

We were able to evaluate the associations of arthritis with a variety of POPs by taking advantage of the NHANES public use data set. In most epidemiologic studies until now, only a limited set of POPs were evaluated. This approach is sensible when the focus is on occupational or accidental exposure to specific POPs. However, in the study of general populations with background exposure to a mixture of POPs, it may be very important to measure a variety of POPs, because the associations of POPs with health outcomes may differ depending on the specific types of POPs in the exposure and the fact that POPs may interact with each other.

Although the strength of association with OA was weaker than with RA, OA still appeared to be associated with some POPs among women. Recently, metabolic factors related to obesity, such as secretion of leptin, have been linked with the onset and progression of OA ([@b12-ehp0115-000883]). Thus, POPs may be involved in the pathogenesis of OA because POPs stored in adipose tissue can cause metabolic disturbances, including over-secretion of leptin ([@b24-ehp0115-000883]). Leptin also plays a key role in a host of autoimmune inflammatory conditions such as RA ([@b30-ehp0115-000883]).

The present study has several limitations. First, the cross-sectional study design in NHANES does not allow inferences to be drawn regarding temporality of events and the causality between POPs and arthritis. Second, misclassification bias is possible because some subjects with a higher POP value but a lower sample volume could be classified in the reference group, or vice versa. Such misclassification would be nondifferential if sample volume is unrelated to the presence of arthritis. Third, as discussed above, the validity of self-reported RA is low ([@b35-ehp0115-000883]) even though it may be also associated with nondifferential misclassification, leading to attenuated strength of association.

In the present study, serum concentrations of both dioxin-like and nondioxin-like PCBs were positively and possibly nonlinearly associated with arthritis among women. The relations were stronger with RA than with OA. These results raise the possibility that background exposures to some POPs may be involved in the pathogenesis of autoimmune diseases such as RA in women. To confirm these relationships, further study in a prospective cohort study would be necessary.

This study was supported in part by the Brain Korea 21 project in 2007.

###### 

Age-adjusted Spearman correlation coefficients[a](#tfn2-ehp0115-000883){ref-type="table-fn"} between five categories of lipid-adjusted POPs (3 PCDDs, 3 PCDFs, 4 dioxin-like PCBs, 5 nondioxin-like PCBs, and 4 OC pesticides) with demographic or health behavior factors by sex.

  Characteristic          PCDDs                                                    PCDFs                                                   Dioxin-like PCBs                                         Nondioxin-like PCBs                                      OC pesticides
  ----------------------- -------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Males                                                                                                                                                                                                                                                      
   Age                    0.53[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    0.35[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}   0.65[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    0.69[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    0.72[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}
   Race                   NS                                                       0.07[\*](#tfn3-ehp0115-000883){ref-type="table-fn"}     NS                                                       NS                                                       −0.29[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}
   Poverty income ratio   NS                                                       NS                                                      0.10[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    0.10[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    −0.17[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}
   BMI                    0.24[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    0.14[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}   0.15[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    NS                                                       0.18[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}
   Current smoker         −0.14[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}   NS                                                      −0.13[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}   NS                                                       NS
  Females                                                                                                                                                                                                                                                    
   Age                    0.60[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    0.52[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}   0.76[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    0.73[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    0.78[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}
   Race                   −0.10[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}   0.08[\*](#tfn3-ehp0115-000883){ref-type="table-fn"}     0.08[\*](#tfn3-ehp0115-000883){ref-type="table-fn"}      0.10[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    −0.35[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}
   Poverty income ratio   NS                                                       0.07[\*](#tfn3-ehp0115-000883){ref-type="table-fn"}     0.09[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    0.12[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    −0.16[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}
   BMI                    NS                                                       NS                                                      NS                                                       −0.17[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}   NS
   Current smoker         −0.19[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}   NS                                                      NS                                                       0.09[\*\*](#tfn4-ehp0115-000883){ref-type="table-fn"}    NS

NS, not significant. For race, white = 1, and others = 0. For current smoker, current = 1, and others = 0.

Before calculating correlation coefficients, detectable values of each POP were individually ranked, and the rank order of the individual POPs in each subclass were summed to arrive at the subclass value; all nondetectable values were ranked as 0.

*p* \< 0.05.

*p* \< 0.01.

###### 

Adjusted[a](#tfn5-ehp0115-000883){ref-type="table-fn"} OR (95% CI) of prevalence of arthritis by quartiles of PCDDs, PCDFs, dioxin-like PCBs, non-dioxin-like PCBs, and OC pesticides in males and females.[b](#tfn6-ehp0115-000883){ref-type="table-fn"}

  Analyte                      \< 25th    25th to \< 50th   50th to \< 75th   ≥ 75th           *p*~trend~
  ---------------------------- ---------- ----------------- ----------------- ---------------- ------------
  Males                                                                                        
   PCDDs                                                                                       
    Cases/participants (no.)   17/191     35/193            47/193            65/192           
    Adjusted OR (95% CI)       Referent   1.5 (0.8--2.9)    1.6 (0.8--3.1)    1.4 (0.7--2.8)   0.48
   PCDFs                                                                                       
    Cases/participants (no.)   30/192     29/192            43/193            62/192           
    Adjusted OR (95% CI)       Referent   0.7 (0.4--1.2)    0.9 (0.5--1.6)    1.1 (0.6--1.9)   0.52
   Dioxin-like PCBs                                                                            
    Cases/participants (no.)   16/192     32/192            47/193            69/192           
    Adjusted OR (95% CI)       Referent   1.3 (0.6--2.5)    1.1 (0.6--2.3)    1.3 (0.6--2.8)   0.56
   Nondioxin-like PCBs                                                                         
    Cases/participants (no.)   12/192     24/192            72/193            56/192           
    Adjusted OR (95% CI)       Referent   1.2 (0.5--2.6)    3.3 (1.6--6.9)    1.5 (0.7--3.4)   0.23
   OC pesticides                                                                               
    Cases/participants (no.)   14/192     28/192            43/193            62/192           
    Adjusted OR (95% CI)       Referent   1.1 (0.5--2.3)    1.5 (0.7--3.2)    1.2 (0.5--2.7)   0.72
  Females                                                                                      
   PCDDs                                                                                       
    Cases/participants (no.)   28/238     54/238            62/238            106/238          
    Adjusted OR (95% CI)       Referent   1.4 (0.8--2.5)    1.0 (0.6--1.9)    1.3 (0.7--2.4)   0.67
   PCDFs                                                                                       
    Cases/participants (no.)   31/237     52/239            63/238            104/238          
    Adjusted OR (95% CI)       Referent   1.2 (0.7--2.1)    0.9 (0.5--1.6)    1.3 (0.8--2.3)   0.51
   Dioxin-like PCBs                                                                            
    Cases/participants (no.)   11/237     36/239            91/238            112/238          
    Adjusted OR (95% CI)       Referent   2.1 (1.0--4.5)    3.5 (1.7--7.4)    2.9 (1.3--6.5)   0.02
   Nondioxin-like PCBs                                                                         
    Cases/participants (no.)   16/238     34/238            89/238            111/238          
    Adjusted OR (95% CI)       Referent   1.6 (0.8--3.1)    2.6 (1.3--5.1)    2.5 (1.2--5.2)   0.02
   OC pesticides                                                                               
    Cases/participants (no.)   19/238     37/238            73/238            121/238          
    Adjusted OR (95% CI)       Referent   1.2 (0.6--2.3)    1.3 (0.7--2.6)    1.8 (0.9--3.9)   0.09

Adjusted for age, race, poverty income ratio, BMI, and cigarette smoking.

Detectable values of each POP were individually ranked, and the rank orders of the individual POPs in each subclass were summed to arrive at the subclass value; all nondetectable values were ranked as 0.

###### 

Adjusted[a](#tfn7-ehp0115-000883){ref-type="table-fn"} OR (95% CI) of prevalence of arthritis by categories of specific POPs belonging to dioxin-like PCBs, nondioxin-like PCBs, and OC pesticides in females.

                                                               Detectable[b](#tfn8-ehp0115-000883){ref-type="table-fn"}                                                      
  ------------------------------------------------- ---------- ---------------------------------------------------------- ---------------- ---------------- ---------------- ---------
  Dioxin-like PCBs                                                                                                                                                           
   2,4,4′,5-Tetrachlorobiphenyl (PCB-74)                                                                                                                                     
    Cases/participants (no.)                        20/334     26/151                                                     53/158           7/154            81/155           
    Adjusted OR (95% CI)                            Referent   2.1 (1.1--4.1)                                             2.9 (1.5--5.6)   3.4 (1.8--6.7)   3.2 (1.5--6.7)   \< 0.01
   2,3′,4,4′,5-Pentachlorobiphenyl (PCB-118)                                                                                                                                 
    Cases/participants (no.)                        21/306     27/162                                                     47/161           74/161           81/162           
    Adjusted OR (95% CI)                            Referent   1.6 (0.8--3.1)                                             2.1 (1.1--3.9)   3.0 (1.6--5.8)   2.2 (1.1--4.5)   0.01
   3,3′,4,4′,5-Pentachlorobiphenyl (PCB-126)                                                                                                                                 
    Cases/participants (no.)                        26/174     25/193                                                     32/195           70/196           97/194           
    Adjusted OR (95% CI)                            Referent   0.9 (0.4--1.6)                                             0.7 (0.4--1.3)   1.3 (0.7--2.3)   1.4 (0.8--2.7)   0.07
   3,3′,4,4′,5,5′-Hexachlorobiphenyl (PCB-169)                                                                                                                               
    Cases/participants (no.)                        26/221     15/183                                                     47/183           76/183           86/182           
    Adjusted OR (95% CI)                            Referent   0.7 (0.3--1.4)                                             1.4 (0.8--2.6)   1.6 (0.9--3.0)   1.6 (0.8--3.1)   0.08
  Nondioxin-like PCBs                                                                                                                                                        
   2,2′,3,4,4′,5-Hexachlorobiphenyl (PCB-138)                                                                                                                                
    Cases/participants (no.)                        26/233     17/180                                                     52/179           73/181           82/179           
    Adjusted OR (95% CI)                            Referent   0.9 (0.4--1.8)                                             1.6 (0.9--2.9)   1.7 (1.0--3.1)   1.3 (0.7--2.5)   0.21
   2,2′,4,4′,5,5′-Hexachlorobiphenyl (PCB-153)                                                                                                                               
    Cases/participants (no.)                        20/199     12/188                                                     50/188           83/189           85/188           
    Adjusted OR (95% CI)                            Referent   0.7 (0.3--1.5)                                             1.7 (0.9--3.3)   2.3 (1.2--4.4)   1.6 (0.8--3.2)   0.06
   2,2′,3,3′,4,4′,5-Heptachlorobiphenyl (PCB-170)                                                                                                                            
    Cases/participants (no.)                        24/344     36/152                                                     47/152           70/152           73/152           
    Adjusted OR (95% CI)                            Referent   2.9 (1.6--5.3)                                             1.9 (1.0--3.6)   2.9 (1.4--5.6)   2.7 (1.3--5.6)   0.03
   2,2′,3,4,4′,5,5′-Heptachlorobiphenyl (PCB-180)                                                                                                                            
    Cases/participants (no.)                        16/234     21/179                                                     48/179           76/181           89/179           
    Adjusted OR (95% CI)                            Referent   1.4 (0.7--2.9)                                             2.1 (1.1--4.2)   2.7 (1.3--5.7)   2.7 (1.2--6.0)   \< 0.01
   2,2′,3,4′,5,5′,6-Heptachlorobiphenyl (PCB-187)                                                                                                                            
    Cases/participants (no.)                        33/396     35/137                                                     46/141           67/140           69/138           
    Adjusted OR (95% CI)                            Referent   1.9 (1.1--3.3)                                             1.9 (1.0--3.4)   2.8 (1.5--5.1)   2.2 (1.1--4.3)   0.01
  OC pesticides                                                                                                                                                              
  * p,p*′-Dichlorodiphenyldichloroethane                                                                                                                                     
    Cases/participants (no.)                        0/0        31/236                                                     44/240           84/239           91/237           
    Adjusted OR (95% CI)                                       Referent                                                   0.9 (0.5--1.6)   1.1 (0.6--2.0)   1.0 (0.5--1.8)   0.93
   Oxychlordane                                                                                                                                                              
    Cases/participants (no.)                        11/185     17/191                                                     51/192           67/192           104/192          
    Adjusted OR (95% CI)                            Referent   1.1 (0.5--2.6)                                             2.6 (1.2--5.4)   2.0 (0.9--4.5)   3.1 (1.3--7.1)   \< 0.01
  * trans*-Nonachlor                                                                                                                                                         
    Cases/participants (no.)                        5/104      20/210                                                     47/215           75/212           103/211          
    Adjusted OR (95% CI)                            Referent   1.4 (0.5--4.0)                                             2.0 (0.7--5.6)   2.4 (0.9--6.8)   2.2 (0.8--6.6)   0.07
   β-Hexachlorocyclohexane                                                                                                                                                   
    Cases/participants (no.)                        17/225     24/181                                                     58/182           74/182           77/182           
    Adjusted OR (95% CI)                            Referent   1.0 (0.5--1.9)                                             1.7 (0.8--3.4)   1.5 (0.7--3.1)   1.4 (0.6--3.2)   0.37

Adjusted for age, race, poverty income ratio, BMI, and cigarette smoking.

For each POP, subjects with serum concentrations \< LOD were regarded as the reference group.

###### 

Adjusted[a](#tfn9-ehp0115-000883){ref-type="table-fn"} OR (95% CI) of prevalence of RA, OA, or unspecified arthritis by categories of dioxin-like PCBs, nondioxin-like PCBs, or OC pesticides in females.[b](#tfn10-ehp0115-000883){ref-type="table-fn"}

  Outcome/analyte              \< 25th    25th to \< 50th   50th to \< 75th   ≥ 75th            *p*~trend~
  ---------------------------- ---------- ----------------- ----------------- ----------------- ------------
  RA                                                                                            
   Dioxin-like PCBs                                                                             
    Cases/participants (no.)   2/228      16/219            17/164            26/152            
    Adjusted OR (95% CI)       Referent   7.6 (1.7--34.4)   6.1 (1.2--29.7)   8.5 (1.6--44.5)   0.05
   Nondioxin-like PCBs                                                                          
    Cases/participants (no.)   4/226      9/213             21/710            27/154            
    Adjusted OR (95% CI)       Referent   2.2 (0.6--7.4)    4.4 (1.3--15.2)   5.4 (1.4--20.3)   \< 0.01
   OC pesticides                                                                                
    Cases/participants (no.)   4/223      13/214            19/184            25/142            
    Adjusted OR (95% CI)       Referent   2.8 (0.8--8.9)    2.7 (0.7--9.8)    3.5 (0.9--14.0)   0.15
  OA                                                                                            
   Dioxin-like PCBs                                                                             
    Cases/participants (no.)   3/229      12/215            28/175            33/159            
    Adjusted OR (95% CI)       Referent   1.9 (0.5--7.2)    2.0 (0.5--7.6)    1.6 (0.4--6.4)    0.97
   Nondioxin-like PCBs                                                                          
    Cases/participants (no.)   4/226      12/216            30/179            30/157            
    Adjusted OR (95% CI)       Referent   1.6 (0.5--5.3)    1.7 (0.5--5.8)    1.2 (0.3--4.5)    0.90
   OC pesticides                                                                                
    Cases/participants (no.)   4/223      12/213            22/187            38/155            
    Adjusted OR (95% CI)       Referent   1.4 (0.4--4.6)    1.3 (0.4--5.2)    2.1 (0.6--8.2)    0.21
  Unspecified arthritis                                                                         
   Dioxin-like PCBs                                                                             
    Cases/participants (no.)   5/231      8/211             38/185            44/170            
    Adjusted OR (95% CI)       Referent   1.2 (0.4--3.9)    3.8 (1.3--11.2)   2.9 (0.9--9.3)    0.06
   Nondioxin-like PCBs                                                                          
    Cases/participants (no.)   7/229      9/213             36/185            43/170            
    Adjusted OR (95% CI)       Referent   1.2 (0.4--3.3)    2.8 (1.0--7.4)    2.8 (1.0--8.3)    0.03
   OC pesticides                                                                                
    Cases/participants (no.)   8/228      10/209            24/188            53/172            
    Adjusted OR (95% CI)       Referent   0.8 (0.3--2.3)    1.0 (0.4--2.8)    1.6 (0.6--4.6)    0.14

Adjusted for age, race, poverty income ratio, BMI, and cigarette smoking.

Detectable values of each POP were individually ranked, and the rank orders of the individual POPs in each subclass were summed to arrive at the subclass value; all nondetectable values were ranked as 0.
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